Hopp til hovedinnhold

MS behandling og oppfølging under COVID-19 pandemien

Publisert:
  1. Zhovtis Ryerson L, Frohman TC, Foley J, et al. . Extended interval dosing of natalizumab in multiple sclerosis. . J Neurol Neurosurg Psychiatry 2016. pmid: 26917698 PubMed  
  2. Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. . Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019. pmid:30956686 PubMed  
  3. Yamout BI, Sahraian MA, Ayoubi NE, Tamim H, Nicolas J, Khoury SJ, et al. Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord 2018 Aug;24:113-6. PubMed  
  4. Kaufman M, Cree BA, de SJ, Fox RJ, Gold R, Hartung HP, et al. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol 2015 Feb;262(2):326-36. PubMed  
  5. Fox RJ, Cree BA, de SJ, Gold R, Hartung HP, Jeffery D, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014 Apr 29;82(17):1491-8. PubMed  
  6. Zhovtis RL, Li X, Goldberg JD, Hoyt T, Christensen A, Metzger RR, et al. Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm 2020 Mar;7(2).
  7. Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord 2019 Jun;31:65-71. PubMed  
  8. Juto A, Fink K, Al NF, Piehl F. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Mult Scler Relat Disord 2020 Jan;37:101468. PubMed